NCT03236766 is a NA clinical trial of Citizens' panels in Mental Disorder, sponsored by University of California, Riverside.

Who is sponsoring NCT03236766?

NCT03236766 is sponsored by University of California, Riverside.

What drugs are being tested in NCT03236766?

Interventions in NCT03236766: Citizens' panels.

What condition does NCT03236766 study?

NCT03236766 studies Mental Disorder.

Is NCT03236766 still recruiting?

NCT03236766 is currently withdrawn. Last updated 4 October 2021.

Last reviewed 2021-10-04 · How we verify

NCT03236766

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Engaging Pacific Islander Perspectives on Mental Illness and Mental Health Services

Withdrawn NA Last updated 4 October 2021

What this trial tests

NA trial testing Citizens' panels in Mental Disorder. Withdrawn.

Timeline

30 September 2017

Primary endpoint
30 November 2018

30 March 2019

Quick facts

Lead sponsor	University of California, Riverside
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Start date	30 September 2017
Primary completion	30 November 2018
Estimated completion	30 March 2019

Drugs / interventions tested

Citizens' panels

Conditions studied

Mental Disorder — all drugs for Mental Disorder →

Sponsor

University of California, Riverside

Who can join

18 and older, male only, with Mental Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will enroll 100 Samoan and 100 Marshallese adults to discuss mental health, mental disorders, and approaches for engaging Pacific Islander adults with mental illness into mental health services.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mental Disorder

Currently open trials in the same condition.

NCT07010614 — Brain Stimulation to the Hippocampus in Schizophrenia · NA · recruiting
NCT06929533 — Pharmacogenomics-Supported Psychotropic Prescribing Trial · NA · recruiting
NCT06813066 — Simulating Psychotherapeutic Sessions With Generative Artificial Intelligence · NA · active not recruiting
NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
NCT06625437 — ACT for HIV-Positive Men · NA · recruiting

Other University of California, Riverside trials

Trials by the same sponsor.

NCT06122688 — By Youth, For Youth: Digital Supported Peer Navigation for Addressing Child Mental Health Care · NA · not yet recruiting
NCT07585630 — RCT of A1Cantus vs. Placebo · Phase 2 · not yet recruiting
NCT07387146 — Community Health Worker Navigation to Support Mental Health · NA · not yet recruiting
NCT07517068 — The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude · EARLY_PHASE1 · active not recruiting
NCT06456372 — Digital Health Intervention for Children With ADHD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03236766 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Riverside
Last refreshed: 4 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03236766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing